
Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that could determine whether affected women can pursue their cases in court.
The multidistrict litigation (MDL), consolidated in Florida, was launched on behalf of women who developed intracranial meningiomas after using Depo-Provera.